Brind.

Resmed reported 11% top-line growth in Europe, alongside strong performance in the U.S. and Canada.

1 report, 1 independent Updated Sep 3

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Resmed Europe

Keep exploring

The entities involved

Resmed
manufacturer of CPAP masks, machines and products that diagnose, treat or help manage respiratory conditions
- ResMed (Australia) emphasized the success of its new product rollouts and R&D investments.Sun 06:42
Europe
terrestrial continent located in north-western Eurasia
- The European Commission aims to strengthen homegrown AI capabilities while global advanced models face usage restrictions.Mon 17:49
- The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49

Coverage

Newest first; wire copies grouped

Sep 3ZacksIs it Worth Retaining ResMed Stock in Your Portfolio Now? ResMed Inc.’s RMD growth in the fourth quarter of fiscal 2025 can be attributed to the robust performance of its Mask business. Its recovery